公开(公告)号：EP3134425A4

公开(公告)日：2018-06-20

申请号：EP15783033

申请日：2015-04-24

Applicant: IMMUSANT INC

Inventor： ANDERSON ROBERT P

IPC: A61K38/10 ,  A61P1/00

CPC classification number: A61K39/0008 ,  A61K38/168 ,  A61K2039/55 ,  A61K2039/577 ,  C07K7/06 ,  C07K7/08 ,  C07K14/55 ,  G01N33/5091 ,  G01N33/564 ,  G01N33/6863 ,  G01N33/6893 ,  G01N2333/415 ,  G01N2333/521 ,  G01N2333/522 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/06 ,  G01N2800/50

Abstract: Provided herein are methods and kits for assaying antigen-specific T cell responses, such as rare autoantigen-specific T cell responses, by measuring a level of IP-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a T cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a T cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having Type 1 Diabetes (TID), Celiac disease or both.

公开(公告)号：EP3290922A1

公开(公告)日：2018-03-07

申请号：EP17182174.7

申请日：2014-08-06

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： MCKNIGHT, Susan Faas ,  COFIELL, Roxanne ,  KUKREJA, Anjli ,  BEDARD, Krystin A. ,  YAN, Yan

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  G01N33/6863 ,  G01N2333/4716 ,  G01N2333/485 ,  G01N2333/522 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5434 ,  G01N2333/545 ,  G01N2333/57 ,  G01N2333/70503 ,  G01N2333/70525 ,  G01N2333/70539 ,  G01N2333/7151 ,  G01N2333/7452 ,  G01N2333/75 ,  G01N2333/775 ,  G01N2333/8139 ,  G01N2333/8146 ,  G01N2333/974 ,  G01N2800/226 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52

Abstract: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Abstract translation: 本公开提供了生物标志物蛋白质，其浓度或活性水平的改变与非典型溶血性尿毒综合征（aHUS）相关或用补体抑制剂对aHUS进行临床有意义的治疗。 还提供了用于询问生物流体中一种或多种生物标志物蛋白质的浓度和/或活性的组合物和方法。 除其他外，组合物和方法可用于评估发展aHUS的风险，诊断aHUS，确定受试者是否正在经历aHUS的第一次急性呈递，监测aHUS的进展或消除，和/或监测对用 补体抑制剂或优化这种治疗。

公开(公告)号：EP3134736A4

公开(公告)日：2018-01-17

申请号：EP15783897

申请日：2015-04-24

Applicant: IMMUSANT INC

Inventor： ANDERSON ROBERT P

IPC: G01N33/68 ,  C07K7/06 ,  C07K7/08

CPC classification number: A61K39/0008 ,  A61K38/168 ,  A61K2039/55 ,  A61K2039/577 ,  C07K7/06 ,  C07K7/08 ,  C07K14/55 ,  G01N33/5091 ,  G01N33/564 ,  G01N33/6863 ,  G01N33/6893 ,  G01N2333/415 ,  G01N2333/521 ,  G01N2333/522 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/06 ,  G01N2800/50

Abstract: Provided herein are methods and kits for assaying antigen-specific T cell responses, such as rare autoantigen-specific T cell responses, by measuring a level of IP-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a T cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a T cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having Type 1 Diabetes (TID), Celiac disease or both.

公开(公告)号：EP2707717B1

公开(公告)日：2017-05-03

申请号：EP12782673

申请日：2012-05-08

Applicant: NESTEC SA

Inventor： HANNAH STEVEN SCOTT ,  SHERRILL SCOTT ,  LI QINGHONG ,  SUN PEICHUAN

IPC: G01N33/564 ,  G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/564 ,  G01N33/6827 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/522 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/102

公开(公告)号：EP3108251A1

公开(公告)日：2016-12-28

申请号：EP15706914.7

申请日：2015-02-12

Applicant: Biomérieux

Inventor： BEDIN, Frédéric ,  FRAGNOUD, Romain

IPC: G01N33/569

CPC classification number: G01N33/56983 ,  G01N2333/185 ,  G01N2333/522 ,  G01N2333/535 ,  G01N2333/81 ,  G01N2800/52 ,  Y02A50/53

Abstract: The invention relates to a method for determining,
in vitro from a blood sample, the probability that a patient will develop a severe case of dengue, wherein: a) the amount of at least one marker, olfactomedin 4, is determined in the blood sample; b) the amount of olfactomedin 4 determined in step a) is compared with a reference amount of said marker obtained from a group of individuals who have been diagnosed with a non-severe case of dengue, and if the amount of olfactomedin 4 determined in step a) is greater than the reference amount in step b), it is determined that the patient will develop a severe case of dengue.

Abstract translation: 本发明涉及用于从血液样品中体外测定患者将发生严重登革热病例的可能性的方法，其中：a）在血液样品中测定至少一种标记物嗅觉觉醒素4的量 ; b）将步骤a）中测定的嗅觉觉醒调节蛋白4的量与参考量的从已诊断患有非严重登革热病例的个体中获得的所述标志进行比较，并且如果在步骤 a）大于步骤b）中的参考量时，确定患者将发生严重的登革热病例。

公开(公告)号：EP2531620B1

公开(公告)日：2016-12-14

申请号：EP11740468.1

申请日：2011-02-04

Applicant: Astute Medical, Inc.

Inventor： ANDERBERG, Joseph ,  GRAY, Jeff ,  MCPHERSON, Paul ,  NAKAMURA, Kevin ,  KAMPF, James, Patrick

IPC: C12Q1/68 ,  G01N33/567

CPC classification number: G01N33/6893 ,  G01N33/6863 ,  G01N33/86 ,  G01N2333/4745 ,  G01N2333/522 ,  G01N2333/96447 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52

公开(公告)号：EP3063542A2

公开(公告)日：2016-09-07

申请号：EP14809984.9

申请日：2014-10-31

Applicant: University of Cape Town

Inventor： MASSON, Lindi ,  PASSMORE, Jo-Ann Shelley

IPC: G01N33/571 ,  G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/571 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/522 ,  G01N2333/545 ,  G01N2800/7095

Abstract: A method of diagnosing an inflammatory condition of the genital tract caused by bacterial vaginosis (BV) or a sexually transmitted infection (STI) in a female subject is described. The method measures the concentration of IP-10 and either of IL-β or IL-α in a sample of cervicovaginal fluid from the subject and compares these to predetermined levels of IP-10 and either of IL-1β or IL-1α, respectively. A down-regulated IP-10 level in the sample or an up-regulated IL-1β or IL-1α level in the sample will be regarded as a positive result, i.e. indicating that there is a high probability that the subject has an STI or BV. The subject could then either be directly treated, e.g. with broad spectrum antibiotics, or referred for appropriate STI screening. The sample can be obtained from a vaginal secretion from the subject. A test kit for performing the method is also described.

公开(公告)号：EP3011345A2

公开(公告)日：2016-04-27

申请号：EP14752744.4

申请日：2014-08-06

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： MCKNIGHT, Susan Faas ,  COFIELL, Roxanne ,  KUKREJA, Anjli ,  BEDARD, Krystin, A. ,  YAN, Yan

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  G01N33/6863 ,  G01N2333/4716 ,  G01N2333/485 ,  G01N2333/522 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5434 ,  G01N2333/545 ,  G01N2333/57 ,  G01N2333/70503 ,  G01N2333/70525 ,  G01N2333/70539 ,  G01N2333/7151 ,  G01N2333/7452 ,  G01N2333/75 ,  G01N2333/775 ,  G01N2333/8139 ,  G01N2333/8146 ,  G01N2333/974 ,  G01N2800/226 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52

Abstract: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Abstract translation: 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法尤其有助于评估发展为高血压的风险，诊断急性淋巴细胞白血症，确定受试者是否正在经历高血压的第一急性表现，监测高血压的进展或减轻，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。

公开(公告)号：EP2718728A1

公开(公告)日：2014-04-16

申请号：EP12731330.2

申请日：2012-06-11

Applicant: Université Libre de Bruxelles ,  Bone Therapeutics S.A. ,  Université de Liège ,  Centre Hospitalier Universitaire de Liège

Inventor： GANGJI, Valérie ,  HAUZEUR, Jean-Philippe ,  DE SENY, Dominique ,  MATHIEU, Myrielle ,  INGELS, Aude ,  RIGUTTO, Sabrina ,  SPRUYT, Delphine ,  BASTIANELLI, Enrico ,  ALBARANI, Valentina ,  PESESSE, Xavier ,  MAILAISE, Michel

IPC: G01N33/68 ,  A61K38/19

CPC classification number: C07K14/5421 ,  A61K38/2053 ,  G01N33/6863 ,  G01N33/6869 ,  G01N2333/522 ,  G01N2333/5412 ,  G01N2333/5421

Abstract: The application teaches a composition comprising one or more pharmaceutical active ingredients selected from the group consisting of interleukin-8 (IL-8 or CXCL8), a functional fragment of IL-8, a functional variant of IL-8, andan agonist of IL-8 receptor,for therapeutic and/orprophylactic interventions in impaired bone fracture healing, such as but not limited to non-union fractures, mal-union fractures,or delayed union fractures.

公开(公告)号：EP2507636A1

公开(公告)日：2012-10-10

申请号：EP10787082.6

申请日：2010-11-29

Applicant: F.Hoffmann-La Roche AG

Inventor： CHIU, Shu-Hui ,  ZHU, Yonghong

IPC: G01N33/576

CPC classification number: G01N33/5767 ,  G01N2333/186 ,  G01N2333/495 ,  G01N2333/522 ,  G01N2333/523 ,  G01N2333/5412 ,  G01N2333/5446 ,  G01N2333/555 ,  G01N2333/70578 ,  G01N2333/7155 ,  G01N2800/52 ,  Y02A90/26

Abstract: The present invention is based on the discovery that in patients infected with Genotype 1 of the Hepatitis C virus (HCV-1) or Genotype 4 HCV (HCV-4) that undergo Triple Therapy treatment, certain biomarkers can be predictive of a patient achieving sustained virologic response